04:43 PM EDT, 08/05/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q2 non-GAAP earnings late Tuesday of $1.54 per diluted share, up from $0.91 a year earlier.

Analysts polled by FactSet expected $1.24.

Revenue for the quarter ended June 30 was $325.7 million, up from $231.4 million a year earlier.

Analysts expected $285.9 million.

For 2025, the biopharmaceutical company is now projecting adjusted EPS of $6 to $6.40 on revenue of $1.28 billion to $1.36 billion, up from its prior forecast of $5.30 to $5.70 on revenue of $1.20 billion to $1.28 billion.

Analysts are looking for $5.43 and $1.25 billion, respectively.

Halozyme shares were up nearly 5% in recent after-hours activity.